Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Phase 1 Completed 89 enrolled Calibr, a division of Scripps Research

RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).

Timeline

Start: 2024-08-19
Primary completion: 2026-06-23
Completion: 2026-06-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CMR316	Unknown	—	Other

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Summary

Timeline

Drugs

Indications